Collegium Pharmaceutical (COLL) Receives New Coverage from Analysts at Janney Montgomery Scott

Share on StockTwits

Investment analysts at Janney Montgomery Scott began coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report issued on Friday, Marketbeat.com reports. The firm set a “buy” rating and a $29.00 price target on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target would indicate a potential upside of 74.80% from the stock’s current price.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald restated a “buy” rating and set a $35.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, February 22nd. Needham & Company LLC restated a “buy” rating and set a $33.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Wednesday, January 16th. BidaskClub downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 9th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research report on Wednesday, January 9th. Finally, SunTrust Banks began coverage on shares of Collegium Pharmaceutical in a research report on Tuesday, March 19th. They set a “buy” rating and a $22.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $28.50.

Shares of COLL stock opened at $16.59 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.26 and a quick ratio of 1.21. The company has a market cap of $544.96 million, a price-to-earnings ratio of -13.94 and a beta of 0.32. Collegium Pharmaceutical has a 12-month low of $13.10 and a 12-month high of $28.91.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.65. The firm had revenue of $73.40 million during the quarter, compared to the consensus estimate of $72.71 million. Collegium Pharmaceutical had a negative net margin of 13.95% and a negative return on equity of 41.12%. The business’s revenue for the quarter was up 579.6% compared to the same quarter last year. During the same period last year, the business posted ($0.54) earnings per share. On average, sell-side analysts anticipate that Collegium Pharmaceutical will post -0.25 EPS for the current fiscal year.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $14.81, for a total transaction of $370,250.00. Following the transaction, the director now directly owns 259,430 shares of the company’s stock, valued at $3,842,158.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 75,000 shares of company stock worth $1,188,500 over the last ninety days. Insiders own 8.08% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System increased its holdings in shares of Collegium Pharmaceutical by 4.8% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock worth $247,000 after purchasing an additional 655 shares during the period. Meeder Asset Management Inc. increased its stake in Collegium Pharmaceutical by 644.8% in the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock valued at $62,000 after acquiring an additional 3,179 shares during the last quarter. Bank of America Corp DE increased its stake in Collegium Pharmaceutical by 17.2% in the fourth quarter. Bank of America Corp DE now owns 23,981 shares of the specialty pharmaceutical company’s stock valued at $412,000 after acquiring an additional 3,525 shares during the last quarter. Teachers Advisors LLC increased its stake in Collegium Pharmaceutical by 6.2% in the third quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock valued at $1,136,000 after acquiring an additional 4,484 shares during the last quarter. Finally, Monarch Partners Asset Management LLC increased its stake in Collegium Pharmaceutical by 19.2% in the fourth quarter. Monarch Partners Asset Management LLC now owns 33,770 shares of the specialty pharmaceutical company’s stock valued at $580,000 after acquiring an additional 5,430 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Read More: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.